BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.15
+2.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 357.9K | 359.7K | 401.0K | 145.8K | 119.8K |
| Cost of Revenue | 28.3K | 23.8K | 28.1K | — | — |
| Gross Profit | 329.6K | 335.9K | 372.9K | 145.8K | 119.8K |
| Operating Expenses | |||||
| R&D Expense | 9.4M | 10.1M | 5.3M | 4.0M | 3.5M |
| SG&A Expense | 5.2M | 5.9M | 6.6M | 11.3M | 15.6M |
| General & Admin Expense | 5.2M | 5.9M | 6.6M | 11.3M | 15.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (110.5K) |
| Total Operating Expenses | 14.6M | 16.0M | 11.9M | 15.4M | 19.0M |
| Cost and Expenses | 14.6M | 16.0M | 12.0M | 15.4M | 19.0M |
| Operating Income (EBIT) | (14.2M) | (15.6M) | (11.6M) | (15.2M) | (18.9M) |
| Non-Operating | |||||
| Interest Income | 171.7K | 266.2K | 616.1K | 552.3K | 11.7K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 171.7K | 266.2K | 616.1K | 552.3K | 11.7K |
| Other Non-Op Income/Expense | 3.2M | 1.4M | 2.6M | 4.8M | 5.6M |
| Non-Operating Income (excl Interest) | (3.2M) | (1.4M) | (2.6M) | (83.3K) | (5.6M) |
| EBT (Pre-Tax Income) | (11.1M) | (14.2M) | (9.0M) | (10.4M) | (13.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.1M) | (14.2M) | (9.0M) | (10.4M) | (13.2M) |
| Earnings from Cont. Ops | (11.1M) | (14.2M) | (9.0M) | (10.4M) | (13.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.1M) | (14.2M) | (9.0M) | (10.4M) | (13.2M) |
| Per Share | |||||
| Basic EPS | ($1.23) | ($1.58) | ($1.16) | ($2.47) | ($3.65) |
| Diluted EPS | ($1.23) | ($1.58) | ($1.16) | ($2.47) | ($3.65) |
| Revenue Per Share | $0.04 | $0.04 | $0.05 | $0.03 | $0.03 |
| Shares | |||||
| Basic Shares Outstanding | 9.0M | 9.0M | 7.8M | 4.2M | 3.6M |
| Diluted Shares Outstanding | 9.0M | 9.0M | 7.8M | 4.2M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | (10.8M) | (14.0M) | (8.8M) | (15.0M) | (13.1M) |
| D&A | 210.6K | 210.0K | 189.1K | 165.7K | 120.5K |
| EBIT | (11.1M) | (14.2M) | (9.0M) | (15.1M) | (13.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026